WO2001026678A1 - Short segments of dap-kinase - Google Patents
Short segments of dap-kinase Download PDFInfo
- Publication number
- WO2001026678A1 WO2001026678A1 PCT/US2000/028312 US0028312W WO0126678A1 WO 2001026678 A1 WO2001026678 A1 WO 2001026678A1 US 0028312 W US0028312 W US 0028312W WO 0126678 A1 WO0126678 A1 WO 0126678A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- kinase
- dap
- peptide
- cells
- apoptosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to DAP-kinase fragments which are critical to the biological function of DAP-kinase as a mediator of apoptosis and can act in a dominant-negative manner when expressed ectopically.
- DAP-kinase Death Associated Protein Kinase
- TKO selection which involved expression of an anti-sense cDNA library in cells, followed by selection of clones that survived in the continuous presence of an apoptotic stimulus.
- specific inhibition of DAP-kinase protein expression by anti-sense RNA protected HeLa cells from apoptosis induced by IFN- ⁇ (Deiss et al, 1995) .
- DAP-kinase was shown to modulate cell death triggered by Fas, TNF- ⁇ (Cohen et al, 1999), and detachment from extracellular matrix (Inbal et al, 1997), indicating its general relevance to apoptosis.
- DAP-kinase is a Ca +2 /calmodulin-regulated serine/threonine kinase that is localized to the cytoskeleton, where it associates with the actin microfilament system (Cohen et al, 1997) .
- the protein carries eight ankyrin repeats, a cytoskeleton binding region and a death domain.
- the multi-domain structure of DAP-kinase and its participation in a wide range of apoptotic systems imply that this protein may interact with various intracellular components to exert its function.
- the present invention further provides a polynucleotide encoding the peptide and a pharmaceutical composition containing the peptide.
- Also provided by the present invention are a method for inhibiting apoptosis associated with DAP kinase by administering the peptide of the invention to a subject in need thereof and a method for screening fragments of a gene product, mediating a selectable phenotype, for being able to act in a dominant negative manner when expressed ectopically.
- Figure 1A illustrates a screening strategy for the isolation of fragments of DAP-kinase that confer resistance to IFN- ⁇ -induced cell killing.
- Purified human DAP-kinase cDNA underwent partial DNase I digestion, and fragments were subcloned into an EBV-derived expression vector to generate a cDNA expression library of random fragments.
- the cDNA library was introduced into HeLa cells, and elements that conferred resistance to apoptosis were isolated and further analyzed.
- Figure IB shows a vector for generation of the DAP- kinase fragmented cDNA library.
- pTKOl an EBV derived vector
- the amino acid sequence of the Flag epitope (SEQ ID NO: 3) encoded by the adaptor is presented above the nucleotide sequence of the adaptor (SEQ ID NOs : 1 and 2).
- Figure 2 lists the cell death-protective fragments of
- DAP-kinase isolated (passed two successive screens) by the genetic screen and shows immediately underneath a schematic representation of DAP-kinase full-length protein with the position of the library-derived protective fragments indicated.
- Figures 3A-3C show present bar graphs and an immunoblot which show that DAP-kinase-derived fragments protect cells from apoptosis.
- FIG 3A apoptosis was induced in 293 cells by transient overexpression of p55/TNF-receptor .
- This receptor was expressed together with an empty vector, a dominant-negative mutant of FADD or DAP-kinase fragments as indicated.
- Transfected cells were identified by GFP expression, and the rate of cell death was scored by typical morphological features. The graph represents average values obtained from three independent experiments, each of which included at least 300 cells.
- Figure 3B 293 cells were induced to undergo apoptosis upon transient overexpression of an activated mutant of DAP-kinase ( ⁇ CaM) . The cells were transfected with this mutant together with either an empty vector or the different fragments as indicated.
- ⁇ CaM activated mutant of DAP-kinase
- Transfectants were identified by GFP expression and apoptosis was scored by morphology as in Figure 3A.
- Figure 3B Immediately below the bar graph in Figure 3B is an immunoblot containing equal amounts of total cell extracts which was reacted with anti-DAP-kinase antibodies to compare the levels of exogenous DAP-kinase in the different transfections (the endogenous levels are below detection levels under these exposure conditions) .
- MCF7 cells were transfected with p55/TNF-receptor together with an empty vector, or the same vector containing the FADD death domain, or different DAP-kinase derived fragments as indicated. Apoptosis was scored as in Figure 3A.
- Figure 4A shows is the sequence alignment of the death domains of DAP-kinase (amino acids 1300-1398; SEQ ID NO: 4) and p75 neurotrophin receptor (amino acids 334-420; SEQ ID NO:5) .
- Amino acids that are included in the protective fragment (1320- 1371) are marked by light gray letters. Amino acids that form the 6 ⁇ -helical structures are emphasized in bold letters and brackets .
- Figure 4B is a model structure of the death domain of DAP-kinase (light gray and dark gray ribbons), constructed by comparative modeling and overlaid on the NMR-based structure of the p75 neurotrophin receptor (lightly shaded ribbon) .
- the six helices ( ⁇ l to ⁇ 6) are accentuated by cylinders.
- regions that are inside and outside the protective fragment are marked with light gray and dark gray, respectively.
- the model was generated as described in Materials and Methods section below .
- Figure 4C is a model structure of the death domain of DAP-kinase presented as electrostatic potential surface. As in Figure 4B, the protective fragment is shown in light gray.
- Figures 5A-5C present bar graphs and an immunoblot which illustrates that deletion of the last 17 amino acids of DAP-kinase potentiates its activity.
- FIG. 5A 293 cells were transfected with either an empty vector, or the same vector carrying the indicated versions of DAP-kinase.
- WT wild type protein
- ⁇ -tail a truncated mutant lacking the 17 C-terminal amino acids
- ⁇ CaM a deletion mutant lacking the calmodulin regulatory region.
- Transfected cells were identified by GFP expression, and the rate of cell death was assessed 24 hours post transfection according to typical apoptotic morphology.
- the graph represents values obtained from three independent experiments, each including at least 300 GFP-positive cells.
- an in vi tro Kinase assay was performed with proteins that were immunoprecipitated from 293 cells transfected with the indicated plasmids, as described in the Materials and Methods section below.
- the assay included an exogenous substrate, MLC, and the relative activity was determined according to the rate of MLC phosphorylation, as quantified using a phosphor-imager .
- Figure 6 is a bar graph illustrating that the death domain protein fragment of DAP-kinase protects a neuroblastoma cell line from ceramide-induced death.
- BE6C cells were treated at low cell density with 30 ⁇ M C6-ceramide at 48 hours post transfection with the following plasmids: pcDNA3 carrying either the DAP-kinase death domain or a non-functional mutated form of the death domain (mutant DD) .
- An empty vector was used as a control, and each transfection also included a GFP plasmid to visualize the transfectants .
- the number of apoptotic cells was scored after seven hours (black bars) and 10 hours (gray bars), respectively.
- Figures 7A-7D show the uptake of rhodamine-labeled derivative of the C-terminal peptide tail by neuronal cells.
- the primary neuronal cultures were prepared by the Banker's methodology in which the hippocampal neurons derived from 18- day-old rat embryos were cultured at low density on cover slips and grown on a supporting layer of glial cells.
- Figures 7A and 7C of the hippocampal neurons were taken under fluorescence microscopy at one hour after adding 30 ⁇ M of the wild type peptide into the culture medium (+peptide; Fig.7A) or DMSO alone (-peptide; Fig.7C).
- Figures 7B (+peptide) and 7D (-peptide) were taken under light microscopy. Similar results were obtained after incubation with the labeled scrambled peptide.
- Figure 8 shows the dose response curve measuring the death protective effects of the wild type peptide in protecting hippocampal neurons from killing by C6-ceramide.
- the chemically synthesized rhodamine-labeled derivative of the C-terminal peptide tail was applied at micromolar concentrations into the culture medium of the primary neurons prepared as described in Figures 7A and 7B.
- the peptide was administered one hour before adding 15 ⁇ M C6-ceramide. Scoring was performed after fourteen hours by the Live/Dead Viability/Cytotoxicity commercial kit.
- Figure 9 is a bar graph which shows illustrates that the wild type DAP-kinase tail peptide but not the scrambled peptide protects hippocampal neurons from apoptosis.
- the two chemically synthesized rhodamine-labeled peptides were applied at 30 ⁇ M concentrations into the culture medium of primary neurons, one hour prior to the addition of C6-ceramide.
- DMSO and ethanol the solvents of the peptides and, respectively, were added to the culture medium. Apoptosis was scored at sixteen hours. The experiments were repeated six times in quadruplicates.
- the present invention includes a genetic screen which identifies minimal fragments of DAP-kinase protein that are critical for its biological function as a mediator of apoptosis and can act in a dominant-negative manner when expressed ectopically.
- GSE genetic suppressor element
- Biologically active cDNA fragments are then isolated from cells expressing the library by a positive functional selection for a specific phenotype.
- This concept has been previously employed to identify functional regions in several genes, including topoisomerase II (Gudkov et al, 1993), kinesin heavy chain (Gudkov et al, 1994; Axenovich et al, 1998) and p53 (Ossovskaya et al, 1996; Gallagher et al, 1997) .
- the screen was adjusted to the conditions and principles of the TKO selection procedure (Deiss et al, 1991) .
- Fragment #1 is 48 amino acids in size and comprises the ankyrin repeats in DAP-kinase.
- Fragment #2 is 55 amino acids in size and comprises the "linker" region of DAP- kinase.
- Fragment #3 is 52 amino acids in size and comprises the death domain of DAP-kinase.
- Fragment # 4 is 17 amino acids in size and comprises the C-terminal tail of DAP-kinase.
- the protein fragments all of which protect cells from apoptosis by inhibiting the complete DAP-kinase protein, are sufficiently stable in the bloodstream so that they can be introduced to cells by conventional delivery methods, i.e., by injection, subcutaneously, etc., as well as by being expressed in vivo through genetically engineered cells. It is particularly interesting to note that Fragment
- One aspect of the present invention is directed to a peptide which is capable of protecting cells from apoptosis by inhibiting DAP kinase.
- Preferred but non-limiting examples of such a peptide include (A) a peptide fragment having the amino acid sequence of SEQ ID NO: 6 from the C-terminal tail of DAP kinase, (B) a DAP kinase peptide fragment of about 48 amino acid residues in length which comprises the amkyrin repeats in DAP kinase, (C) a DAP kinase peptide fragment of about 55 amino acid residues in length which comprises the linker region of DAP kinase, and (D) a DAP kinase peptide fragment of about 52 amino acid residues in length which comprises the death domain of DAP kinase.
- This aspect of the invention also encompasses shorter fragments, analogs and derivatives of the DAP kinase peptide fragment as well as an elongated peptide in which either or both the N- and C-termini of the peptide is extended by 1-4 residues, preferably Asp or Glu. Extension of the termini of the peptide with Asp or Glu residues enhances the water solubility property of the peptide .
- a "fragment" of the peptide of the present invention refers to any subset of the molecule, that is, a shorter peptide. Fragments of interest are those which are capable of protecting cells from apoptosis by inhibiting DAP kinase. Such "shorter" fragments can be generated by a systematic sequential deletion of amino acid residues from the peptide which would minimize, if possible, the size/length of the peptide without interfering with its inhibitory activity. Alternatively, systematic deletion of the DNA encoding the peptide, such as by nested deletions using Bal31 nuclease, can be used to generate DNA which would express and produce "shorter" fragments.
- An analog of the peptide according to the present invention has an amino acid sequence essentially corresponding to that of the peptide of the invention.
- the term "essentially corresponding to” is intended to comprehend analogs with minor changes to the sequence of the peptide which do not affect the basic characteristics thereof, particularly insofar as its ability to be inhibit DAP kinase.
- the type of changes which are generally considered to fall within the "essentially corresponding to” language are those which would result from conventional mutagenesis techniques of the DNA encoding the peptide of the invention, resulting in a few minor modifications, and screening for the desired activity in the manner discussed below.
- the analog is a variant of the native peptide fragment of DAP kinase which has an amino acid sequence having at least 70% identity to the native amino acid sequence and retains the DAP kinase inhibitory activity thereof. More preferably, such a sequence has at least 85% identity, at least 90% identity, or most preferably at least 95% identity to the native sequence.
- Variant peptides may be conveniently prepared by direct chemical synthesis of the variant peptide, using methods well known in the art. At the genetic level, these variants can ordinarily be prepared by site-directed mutagenesis (as exemplified by Adelman et al .
- sequence identity means that the sequences are compared as follows .
- the sequences are aligned using Version 9 of the Genetic Computing Group's GAP (global alignment program), using the default (BLOSUM62) matrix (values -4 to +11) with a gap open penalty of -12 (for the first null of a gap) and a gap extension penalty of -4 (per each additional consecutive null in the gap) .
- BLOSUM62 global alignment program
- percentage identity is calculated by expressing the number of matches as a percentage of the number of amino acids in the claimed sequence .
- Analogs in accordance with the present invention may also be determined in accordance with the following procedure.
- Peptides encoded by any nucleic acid, such as DNA or RNA which hybridize to the complement of the native DNA or RNA under highly stringent or moderately stringent conditions, as long as that peptide maintains the biological activity of the native sequence, are also considered to be within the scope of the present invention.
- Stringency conditions are a function of the temperature used in the hybridization experiment, the molarity of the monovalent cations and the percentage of formamide in the hybridization solution. To determine the degree of stringency involved with any given set of conditions, one first uses the equation of Meinkoth et al . (1984) for determining the stability of hybrids of 100% identity expressed as melting temperature Tm of the DNA-DNA hybrid:
- Tm 81.5°C + 16.6 (LogM) + 0.41 (%GC) - 0.61 (% form) - 500/L
- M is the molarity of monovalent cations
- %GC is the percentage of G and C nucleotides in the DNA
- %form is the percentage of formamide in the hybridization solution
- L is the length of the hybrid in base pairs.
- highly stringent conditions are those which are tolerant of up to about 15% sequence divergence, while moderately stringent conditions are those which are tolerant of up to about 20% sequence divergence.
- examples of highly stringent (12-15°C below the calculated Tm of the hybrid) and moderately (15-20°C below the calculated Tm of the hybrid) conditions use a wash solution of 2 X SSC (standard saline citrate) and 0.5% SDS at the appropriate temperature below the calculated Tm of the hybrid.
- the ultimate stringency of the conditions is primarily due to the washing conditions, particularly if the hybridization conditions used are those which allow less stable hybrids to form along with stable hybrids. The wash conditions at higher stringency then remove the less stable hybrids.
- a common hybridization condition that can be used with the highly stringent to moderately stringent wash conditions described above is hybridization in a solution of 6 X SSC (or 6 X SSPE) , 5 X
- Denhardt ' s reagent 0.5% SDS, 100 ⁇ g/ml denatured, fragmented salmon sperm DNA at a temperature approximately 20° to 25°C below the Tm. If mixed probes are used, it is preferable to use tetramethyl ammonium chloride (TMAC) instead of SSC (Ausubel, 1987, 1998) .
- TMAC tetramethyl ammonium chloride
- “Functional derivatives” or “derivatives” as used herein covers chemical derivatives which contain additional chemical moieties not normally part of the peptide and which may be prepared from the functional groups that occur as side chains on the residues or the N- or C-terminal groups by means well known in the art, and are included in the invention as long as they remain pharmaceutically acceptable, i.e., they do not destroy the DAP kinase inhibitory activity of the corresponding peptide as described herein, and do not confer toxic properties on compositions containing it .
- Suitable derivatives may include aliphatic esters of the carboxyl of the carboxyl groups, amides of the carboxyl groups by reaction with ammonia or with primary or secondary amines, N-acyl derivatives or free amino groups of the amino acid residues formed with acyl moieties (e.g., alkanoyl or carbocyclic aroyl groups) or O-acyl derivatives of free hydroxyl group (e.g., that of seryl or threonyl residues) formed with acyl moieties.
- Such derivatives may also include for example, polyethylene glycol side-chains which may mask antigenic sites and extend the residence of the complex or the portions thereof in body fluids . Non-limiting examples of such derivatives are described below.
- Cysteinyl residues most commonly are reacted with alpha-haloacetates (and corresponding amines), such as chloroacetic acid or chloroacetamide, to give carboxymethyl or carboxyamidomethyl derivatives. Cysteinyl residues also are derivatized by reaction with bromotrifluoroacetone, alpha-bromo- beta- (5-imidazoyl) propionic acid, chloroacetyl phosphate, B alkylmaleimides, 3-nitro-2-pyridyl disulfide, methyl-2-pyridyl disulfide, p-chloromercuribenzoate, 2-chloromercuri-4- nitrophenol, or chloro-7-nitrobenzo-2-oxa-l , 3-diazole .
- Histidyl residues are derivatized by reaction with diethylprocarbonate at pH 5.5-7.0 because this agent is relatively specific for the histidyl side chain.
- Parabromophenacyl bromide also is useful; the reaction is preferably performed in 0.1 M sodium cacodylate at pH 6.0.
- Lysinyl and amino terminal residues are reacted with succinic or other carboxylic acid anhydrides. Derivatization with these agents has the effect of reversing the charge of the lysinyl residues.
- Other suitable reagents for derivatizing alpha-amino-containing residues include imidoesters such as methyl picolinimidate; pyridoxal phosphate; pyridoxal; chloroborohydride; trinitrobenzenesulfonic acid; 0- methylisourea; 2, 4-pentanedione; and transaminase-catalyzed reaction with glyoxylate.
- Arginyl residues are modified by reaction with one or several conventional reagents, among them phenylglyoxal , 2,3- butanedione, 1 , 2-cyclodexanedione, and ninhydrin .
- Derivatization of arginine residues requires that the reaction be performed in alkaline conditions because of the high pK a of the guanidine functional group. Furthermore, these reagents may react with the groups of lysine as well as the arginine epsilon- amino group.
- Carboxyl side groups are selectively modified by reaction with carbodiimides (R'-N-C-N- R') such as l-cyclohexyl-3- [2-morpholinyl- (4- ethyl) ] carbodiimide or l-ethyl-3- ( 4-azonia-4 , 4-dimethlypentyl ) carbodiimide .
- carbodiimides R'-N-C-N- R'
- carbodiimides R'-N-C-N- R'
- carbodiimides Rosinyl or glutamyl
- aspartyl and glutamyl residues are converted to asparaginyl and glutaminyl residues by reaction with ammonium ions .
- Glutaminyl and asparaginyl residues are frequently deamidated to the corresponding glutamyl and aspartyl residues. Alternatively, these residues are deamidated under mildly acidic conditions. Either form of these residues falls
- derivatives is intended to include only those derivatives that do not change one amino acid to another of the twenty commonly-occurring natural amino acids.
- salts herein refers to both salts of carboxyl groups and to acid addition salts of amino groups of the complex of the invention or analogs thereof.
- Salts of a carboxyl group may be formed by means known in the art and include inorganic salts, for example, sodium, calcium, ammonium, ferric or zinc salts, and the like, and salts with organic bases as those formed, for example, with amines, such as triethanolamine, arginine or lysine, piperidine, procaine and the like.
- Acid addition salts include, for example, salts with mineral acids, such as, for example, hydrochloric acid or sulfuric acid, and salts with organic acids, such as, for example, acetic acid or oxalic acid.
- any such salts must have substantially similar biological activity to the complex of the invention or its analogs .
- analogs the 17-mer Fragment #4, which has the sequence
- Serine (S) residues in positions 1, 4, 7, 10, 12, 13 and 16 may be substituted by amino acids capable of hydrogen bond formation, i.e., threonine, or the non- natural ammo acid homoserme.
- Other possible substitutions are with non-charged and weakly or moderately hydrophobic residues such as Gly or Ala.
- Cys 2 (C) can be replaced by natural or non-natural, non-charged, ammo acids such as Gly, Ala, Val, Ser,
- Asn 3 and Asn 9 (N) can be replaced by Gin, as well as by Asp or Glu. These alterations may lead to better solubility of the peptides .
- Gly 5 (G) can be replaced by different aliphatic non- charged natural or unnatural residues such as Ala, ⁇ - ammopropionic acid.
- Thr 6 (T) can be replaced by aliphatic non-charged and rather moderately or weakly hydrophobic ammo acids, such as Ser, Gly, Ala and the like.
- Tyr 8 (Y) can be replaced by aromatic residues, natural and unnatural residues such as Phe, Trp, p-ammo-Phe, methylated-Phe, halogen derivatives of Phe and Tyr, as well as by aliphatic hydrophobic residues such as Leu, He, Nle.
- Highly hydrophobic residues on I 11 , V 14 , V 15 can be replaced by hydrophobic aliphatic or aromatic residues, natural or unnatural, such as Leu, Nor-Leu (Nle) , Nor-Val (Nva) , Met, Phe, methylated-Phe, Trp, Tic, Homo-Leu.
- Arg 17 (R) can be substituted by positively-charged residues, natural or unnatural, such as Lys, N - alkylated-Lys, Orn and its alkylated derivatives, N w - alkylated and di-alkylated derivatives of Arg. It will be appreciated by those of skill in the art that the same type of consideration for amino acid substitutions can made for the other inhibitory peptide fragments of DAP kinase.
- Elongation of the peptide chain by various amino acid (1-4 residues) especially related to the natural sequence (at both N- and C-terminals) may yield active derivatives.
- Addition of negatively charged residues, such as Glu or Asp, may enhance solubility with preservation of activity.
- N-terminal succinylation or glutarylation is also feasible as chemical derivatives of the peptide.
- modifications can be performed on water-soluble (i.e., peptides extended at either terminals by addition of Asp or Glu residues [1-4]) peptides.
- PEG polyethylene glycol chains
- the association between the peptide chain and the extension may be through an amide (CO—NH) formation or via bonding such as —CH 2 —N(H)- or via terminal SH moiety, e.g., —CH 2 -Cys-peptide (—CH 2 —S—) .
- Biological assessments for the DAP kinase inhibitory activity of the peptides, and analogs and derivatives thereof, are quite readily performed in the well-calibrated system of glutamate-treated hippocampal neurons.
- the inhibitory activity of the peptides, and analogs and derivatives thereof, can also be assayed with neuronal cell lines that undergo apoptosis m response to various insults including deprivation of growth factors, ceramides or killing cytokmes (the latter being perhaps a more practical screening system) .
- the response of retinal ganglion cells to two defined injuries, glutamate eye injections and crush injury of the optic nerve, in test animals is preferably used as in vivo model systems for testing the efficacy of peptides, and analogs and derivatives thereof, in protecting neuronal cells from apoptosis.
- the reasons being: a) The relevance of DAP-kmase to the death of retinal ganglion cells has been recently established in the DAP-kmase KO mice. The laboratory of the present inventors found that m DAP-kmase deficient mice the number of retinal ganglion cells which survived after intravitreal glutamate injection or the crush injury of the optic nerve was higher in a statistically significant extent.
- the eye bulb is considered as an isolated box where compounds can be introduced by intravitreal injections, and be effective without being diluted by excess of fluid. Thus peptide injections may be maximally effective.
- the experimental system is a model for different human pathologies such as glaucoma. The best peptide derivatives will be injected nto the vitreal body of a wild- type mice at different time points before and after the crush injury of the optic nerve or glutamate administration. The number of survival cells m the retina will be assessed by counting. The effects will be compared to the protective effects obtained by the deletion of DAP-kmase the KO mice m order to evaluate the efficacy of the peptide.
- the peptides, and analogs and derivatives thereof, of the present invention can be combined with a pharmaceutically acceptable carrier, and optionally other therapeutic and/or prophylactic ingredients.
- the carriers must be "acceptable” the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- the peptide can be administered m the form of a combination of the peptide with a pharmaceutically acceptable carrier.
- the compositions of the present invention thus include at least one peptide analog or derivative thereof along with a pharmaceutically acceptable carrier.
- compositions suitable for oral administration wherein the carrier is a solid are most preferably presented as unit dose formulations, such as boluses, capsules, and the like, as well as sachets or tablets, each containing a predetermined amount of the active ingredient.
- a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared by compressing m a suitable machine the active conjugate a free-flowing form, such as a powder or granules optionally mixed with a binder, lubricant, terdiluent, lubricating, surface active or dispersing agent. Molded tablets may be made by molding the active conjugate with an inert liquid diluent.
- Tablets may be optionally coated and, if uncoated, may optionally be scored.
- Capsules may be prepared by filling the active conjugate, either alone or in admixture with one or more accessory ingredients, into the capsule cases and then sealing them in the usual manner. Cachets are analogous to capsules wherein the active conjugate together with any optional accessory ingredient is sealed in a rice paper envelope.
- Pharmaceutical formulations suitable for oral administration in which the carrier is a liquid may conveniently be presented as a solution in an aqueous liquid or a non-aqueous liquid, or an oil-in-water or water-in-oil liquid emulsion.
- Pharmaceutical formulations suitable for parenteral administration are conveniently presented in unit dose or multi- dose container which are sealed after introduction of the formulation until required for use.
- the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingredients, such as diluents, buffers, flavoring agents, binders, surface active agents, thickeners, lubricants, preservative (including anti-oxidants ) and the like, and substances included for the purpose of rendering the formulation isotonic with the blood of the intended recipient.
- additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface active agents, thickeners, lubricants, preservative (including anti-oxidants ) and the like, and substances included for the purpose of rendering the formulation isotonic with the blood of the intended recipient.
- the pharmaceutical formulations may be any formulation in which the active compound may be administered and include those suitable for oral or parenteral (including intramuscular and intravenous) administration.
- the formulations may, where appropriate, be conveniently presented in discrete dosage units and may be prepared by any of the methods well known in the art of pharmacy. All of the methods include the step of bringing into association the active compound with liquid carriers or finely divided solid carriers of both and then, if necessary, shaping the product into the desired formulation.
- a patient in need thereof is treated with a therapeutically effective amount of at least one of the peptides of the present invention.
- the peptide according to the present invention are relatively stable in the bloodstream, they can be administered by any conventional means of administering peptides. Alternatively, the peptide can be administered by causing expression of the peptide in vivo .
- an effective amount refers to an amount of the active agent which is capable of inducing a therapeutic alteration in the physiological state of the patient receiving the active agent as a result of inhibiting DAP kinase activity. Such an amount can be empirically determined by those of skill in the art.
- this invention provides a method for treating a disease or a disorder associated with apoptosis comprising introducing into the cells of an affected individual a therapeutically effective amount of the active agent, thereby preventing apoptosis of the cells.
- Another aspect of the present invention is a method for generally screening fragments of a gene product, mediating a selectable phenotype, for capability of acting in a dominant negative manner when expressed ectopically.
- the preferred embodiment of this method is applied to DAP kinase as the gene product. This method involves:
- A Fragmenting a cDNA encoding a gene product, which mediates a selectable phenotype, to obtain random cDNA fragments .
- B Inserting the random cDNA fragments into an EBV- based episomal shuttle vector capable of propagation in bacterial and mammalian cells to generate a library of random cDNA fragments, wherein the random cDNA fragments are operably linked to a promoter for expressing the random cDNA fragments and the EBV-based episo al shuttle vector has a selectable marker and an interferon responsive enhancer element which stimulates the expression of the random cDNA fragment from the operably-linked promoter.
- peptide fragments of DAP kinase which act in a dominant negative manner to DAP kinase, are isolated.
- operably linked is intended to refer to an "operable linkage" in which the regulatory DNA sequences (i.e., promoter) and the DNA sequence sought to be expressed are connected in such a way as to permit gene expression.
- the precise nature of the regulatory regions needed for gene expression may vary from organism to organism, but shall in general include a promoter region as well as the DNA sequence which, when transcribed into RNA, will signal the initiation of protein synthesis.
- Full length DAP-kinase cDNA a 5 Kb fragment, was excised from a Bluescript plasmid and purified. Five ⁇ g of this cDNA were subjected to partial DNase I (Sigma) digestion as described (Gudkov et al, 1997) . The reaction was stopped by addition of EDTA to a final concentration of 25 mM, at different time points, to obtain fragment preparations of various average lengths (between 50 bp and 2 Kb) .
- the vector in which the library was constructed was based on pTKOl that was previously developed in the laboratory of the present inventors (Deiss et al, 1991) .
- MCF7 and HeLa cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Gibco) supplemented with 10% fetal calf serum (FCS; Biolab) , 2 mM glutamine, and 100 U/ml penicillin and streptomycin (Gibco) .
- DMEM Dulbecco's modified Eagle's medium
- FCS fetal calf serum
- Gibco penicillin and streptomycin
- a transfection mix for each plate included 1 ⁇ g of EGFP encoding plasmid (Clontech) , 3 ⁇ g of the "killing" plasmid (pcDNA3 carrying either p55-TNF-receptor, or DAP-kinase ⁇ CaM) , and 9 ⁇ g of either empty vector or a plasmid carrying the library fragments.
- pcDNA3 carrying either p55-TNF-receptor, or DAP-kinase ⁇ CaM
- 9 ⁇ g of either empty vector or a plasmid carrying the library fragments To compare killing potency of different forms of DAP-kinase, 1 ⁇ g pEGFP and 10 ⁇ g of pcDNA3 were used carrying each of the indicated forms. Apoptosis was assessed 24 hours after transfection under a fluorescent microscope and according to morphological features .
- Cell pellets were lysed in PLB buffer, separated by SDS-PAGE and blotted onto nitrocellulose membranes as described (Cohen et al, 1997). Filters were blocked in PBS plus 0.1% Tween 20 and 10% w/v skim dry milk, and then incubated with anti-DAP-kinase monoclonal antibodies (Sigma) diluted 1:1000 for 1 hour. The filters were washed in PBS-Tween, and then incubated with horseradish peroxidase-conjugated goat anti-mouse antibody (Jackson) . Antibodies were visualized by enhanced chemiluminescence according to manufacturer's instructions (Supersignal, Pierce) .
- 293 cells were plated one day before transfection (10 6 cells/9 cm plate) and transfected by the CaP0 4 procedure with 1 ⁇ g pEGFP and 10 ⁇ g of pcDNA3 carrying each of the indicated forms of DAP-kinase, all tagged with an HA epitope at their N- terminus .
- Cell pellets were lysed in PLB buffer as described (Cohen et al, 1997), and immunoprecipitation of recombinant DAP- kinase protein from 1 mg total extract was performed with 3 ⁇ l of anti-HA monoclonal antibodies in 500 ⁇ l of PLB supplemented with protease and phosphatase inhibitors for two hours at 4°C.
- the immunoprecipitates were washed three times with PLB, and once with reaction buffer (50 mM Hepes pH 7.5, 8 mM MgCl 2 and 0.1 mg/ml BSA) .
- the proteins bound to the beads were incubated for 10 minutes at 30°C in 50 ⁇ l of reaction buffer containing 15 ⁇ Ci[ ⁇ - 32 P] ATP (3 pmole), 50 ⁇ M ATP, 2 ⁇ g MLC (Sigma), CaCl 2 (0.1 mM) and bovine calmodulin (1 ⁇ M, Sigma) . Protein sample buffer was added to terminate the reaction, and after boiling the proteins were analyzed on 12% SDS-PAGE.
- the gel was blotted onto a nitrocellulose membrane, 32 P-labeled proteins were visualized by autoradiography, and the rate of relative MLC phosphorylation was measured using a phosphor-imager .
- DAP- kinase levels were determined by immunoblotting with monoclonal anti DAP-kinase antibodies.
- the library was constructed in pTKOl (Deiss et al, 1991), an EBV-based episomal vector, that carries an IFN- responsive enhancer element (ISRE), which stimulates the expression of the library inserts during selection, and was previously shown to be very effective in this procedure (Deiss et al, 1991) .
- pTKOl EBV-based episomal vector
- ISRE IFN- responsive enhancer element
- Into this vector a suitable expression cassette was first introduced, which provided an initiator methionine in a favorable translation initiation context within a Flag epitope, followed by a cloning site and stop codons in all three reading frames ( Figure IB) . DAP-kinase cDNA fragments were generated by incomplete DNase I digestion, and ligated into the vector.
- the DAP-kinase cDNA library was introduced into HeLa cells by transfection, and the cells were then subjected to double selection with hygromycin B and IFN- ⁇ for three weeks. Cell colonies that survived this prolonged selection were pooled, and episomes were isolated by Hirt ' s extraction and used to transform bacteria.
- the cDNA inserts of plasmids from 70 randomly chosen bacterial colonies were amplified by PCR and sequenced. Thirteen fragments turned out to be inserted in a sense orientation, and out of the sense fragments, 18 clones encoded peptides in the authentic reading frame of DAP-kinase. Of the 18 clones, four fragments appeared only once, and the rest appeared multiple times corresponding altogether to nine different fragments. Since the aim was to study the function of different structural motifs of the protein, attention was particularly concentrated on those sense fragments in the correct frame. To distinguish between functionally active and false positive peptides, the biological function of individual fragments was tested as detailed below.
- the HeLa/IFN- ⁇ system from which DAP-kinase was isolated, was suitable for the first round of functional selection, since in this system a single genetic change was sufficient to yield a weak, yet selectable phenotype of increased survival in a population of cells subjected to a long- term selection (Deiss et al, 1991) . However, as this characteristic of the system may also lead to a significant level of non-specific background, fragments obtained in this selection were individually tested by a secondary screen.
- apoptosis induced by high levels of p55 TNF receptor was used. This is a system in which an essential role for DAP-kinase has been previously established (Cohen et al, 1999) . In this assay system one could rapidly examine the ability of the isolated fragments to inhibit DAP- kinase function and, thus, protect cells from apoptosis. To this aim, the p55 TNF-receptor was transfected into human kidney epithelial 293 cells together with either an empty pTKOl vector or with a vector carrying individual fragments from the first selection, and the level of apoptosis was assessed 24 hours later.
- Transfected cells were identified by GFP expression and the rate of apoptosis was scored microscopically according to typical morphological features.
- a peptide was defined positive if its co-introduction into cells reduced the extent of TNF- receptor-induced apoptosis by more than 50%.
- the present inventors utilized an activated mutant of DAP-kinase, in which a deletion of the calmodulin binding and regulatory regions rendered the kinase domain constitutively active, thereby generating a potent death-inducing protein (Cohen et al, 1997).
- the activated DAP-kinase (designated ⁇ CaM) was transfected into 293 cells together with either an empty vector, or the same vector carrying the different selected cDNA fragments.
- expression of the various peptides reduced the extent of apoptosis induced by the activated DAP-kinase, without affecting its protein expression levels.
- Fragment (#3) was derived from the death domain, a conserved module whose critical role in DAP-kinase-mediated apoptosis has been established (Cohen et al, 1999) .
- 3D three-dimensional model structure of the death domain was constructed. The molecular modeling was based on the sequence similarity between DAP-kinase death domain and the closely related intracellular domain of the p75 neurotrophin receptor, for which an NMR structure was recently published (Liepinsh et al, 1997) .
- the predicted structure of the DAP-kinase death domain consists of 99 amino acid residues that fold to form 6 ⁇ -helices (Figure 4B) .
- helices ⁇ l, ⁇ 5 and ⁇ 6 lie parallel to each other and are perpendicular to helices ⁇ 2 , ⁇ 3 and ⁇ 4.
- One notable difference between the two death domains is the presence of longer loops extending between helices ⁇ l and ⁇ 2 and helices ⁇ 3 and ⁇ 4 of the DAP-kinase death domain. Since these loops are unique to DAP-kinase, they may contribute to the specificity of interaction with other proteins .
- the region marked in light gray represents Fragment #3, which was isolated as an effective inhibitor of DAP-kinase.
- This region whose exact composition is marked in the sequence alignment ( Figure 4A) , completely spans helices ⁇ 2 , ⁇ 3 and ⁇ 4 , which, as revealed by the molecular model and emphasized in Figure 4C, are clustered to form a structurally distinct element.
- This substructure is stabilized by hydrophobic interactions, particularly between helices ⁇ 2 and ⁇ 4, that are likely to direct correct folding of the peptide even when expressed separately, and hence allow binding of this distinct module to its putative target protein (s) .
- N- terminal Flag epitope is not expected to interfere with the folding of the peptide.
- the Flag tag is composed mostly of hydrophilic residues, and second, since it is connected to a 9-amino acid long stretch of the loop between helices ⁇ l and ⁇ 2 , which physically separates the tag from the core of the module.
- Fragment #3 constitutes a defined substructure in the death domain, a feature that may underlie its effective biological function.
- this fragment was deleted from the full-length protein, and the rate of apoptosis induced by WT DAP-kmase (DAPk-WT) and truncated DAP-kmase (DAPk-tail) was compared.
- DAPk-WT WT DAP-kmase
- DAPk-tail truncated DAP-kmase
- DAP-kmase then a deletion should result m potentiation of the death-promoting function of the protein.
- a tail-truncated version of the protein was generated by introducing a stop codon at position 1415, thus, removing the last 17 ammo acids of the protein (tail mutant) .
- Quantitative apoptosis assays were then used to compare the potency of this deletion mutant to that of the wild type protein.
- the constitutively active kinase mutant ( ⁇ CaM) was used m these assays as a control for gam of function. It was found that truncation of the last 17 ammo acids greatly potentiated the ability of DAP-kmase to induce apoptosis 293 cells ( Figure 5A) .
- the truncated tail mutant displayed kinase activity that was indistinguishable from that of the WT protein, whereas the ⁇ CaM mutant, carrying an activated kinase domain, clearly showed an increased kinase activity (Figure 5C) .
- the enhancement of killing potency could not be attributed to a higher kinase activity.
- the DAP-kinase "death domain” and the C-terminal peptide were used in order to assess the participation of DAP- kinase in neuronal cell death. These specific inhibitory protein domains were first tested in neuronal cell lines subjected to undergo apoptosis by ceramides and then in primary neurons aiming at elaborating conditions in which the delivery into primary hippocampal neurons will be as simple as possible.
- an immortalized human neuroblastoma cell line (BE6C) was transfected with pcDNA3 expression vector carrying either the death domain (CAPk-DD) , a non-functional mutated form of the death domain (CAPk-mDD-- cf .
- Wi ld type S CNS GT S YNS I S SVVS R ( SEQ I D NO : 6 ) Scrambled : S C S RSVS GSN SYTVN I S ( SEQ I D NO : 7 )
- Tetramethylrhodamine isothiocyanate was covalently linked to the N-terminus of the peptide. This technique increased the hydrophobicity of the peptide and made it possible to follow its entry into cells by fluorescence microscopy. When applied at micromolar concentrations into the culture medium of HeLa cells and primary hippocampal neurons, the cells were rapidly labeled, i.e., within an hour, and if removed by washing after the first hour, the label persisted in the cells for a few additional hours, decaying gradually. This rhodamine-coupled peptide was used in the experiments shown in Figures 7-9, where it effectively protected hippocampal neurons from ceramide- induced cell death.
- the chemically synthesized rhodamine-labeled derivatives of the C-terminal peptide tail when applied to hippocampal neurons at day three of culturing, resulted in almost 100% efficiency of intracellular delivery.
- DAP-kinase Since DAP-kinase is expressed in growing cells, its ability to induce cell death should be tightly regulated and activated only upon apoptotic triggers.
- One level of regulation relates to the catalytic activity, that is enhanced by binding of Ca +2 /Calmodulin (Cohen et al, 1997) .
- a second regulatory mechanism was revealed in this study and engages the C-terminal amino acid tail that immediately follows the death domain.
- Fragment #4 consisting of the very last 17 amino acids of DAP- kinase, can inhibit in trans the function of the complete protein.
- the biological activity of this tail could hypothetically be modeled in one of two ways: (1) the tail is normally required for execution of DAP-kinase function by interaction with another protein, and excess of the peptide sequesters a cellular downstream effector; or (2) the tail is involved in negative regulation of DAP-kinase, probably through intramolecular folding that prevents interaction of other regions in DAP-kinase with downstream effectors and, therefore, excess peptide can inhibit the effect of DAP-kinase on its targets.
- Fas-associated phosphatase (FAP-1) plays in signal transduction is unclear (Cuppen et al, 1997; Yanagisawa et al, 1997), its association with Fas inhibited death induction in certain cell systems. In this latter case, excess peptide which titrated out the inhibitor stimulated, rather than inhibited, apoptosis, a scenario which does not apply for DAP-kinase tail.
- the apparent difference in electrophoretic mobility between the WT and the tail-deleted proteins is larger than predicted by size differences alone, suggesting that the tail may undergo a post translational modification, perhaps phosphorylation, to regulate its activity.
- DAP-kinase The study described here identified functional regions in DAP-kinase and established the tools to perform a more comprehensive screen.
- the peptides which have been already identified can serve as a basis for isolation of proteins that interact with these regions in DAP-kinase, and for generating specific low molecular mass inhibitors for this protein, that can be used to modulate apoptotic processes.
- DAP-kinase is a Ca2+/calmodulin-dependent , cytoskeletal-associated protein kinase, with cell death- inducing functions that depend on its catalytic activity
- EMBO J 16(5) :998-1008 a Ca2+/calmodulin-dependent , cytoskeletal-associated protein kinase, with cell death- inducing functions that depend on its catalytic activity
- GSEs genetic suppressor elements
- FAP-1 a protein tyrosine phosphatase that associates with Fas
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU10827/01A AU1082701A (en) | 1999-10-13 | 2000-10-13 | Short segments of dap-kinase |
JP2001529739A JP2003516122A (en) | 1999-10-13 | 2000-10-13 | Short segment of DAP kinase |
IL14909300A IL149093A0 (en) | 1999-10-13 | 2000-10-13 | Short segments of dap-kinase |
CA002387541A CA2387541A1 (en) | 1999-10-13 | 2000-10-13 | Short segments of dap-kinase |
EP00972123A EP1223970A4 (en) | 1999-10-13 | 2000-10-13 | Short segments of dap-kinase |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15910799P | 1999-10-13 | 1999-10-13 | |
US60/159,107 | 1999-10-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001026678A1 true WO2001026678A1 (en) | 2001-04-19 |
WO2001026678A9 WO2001026678A9 (en) | 2002-08-01 |
Family
ID=22571109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/028312 WO2001026678A1 (en) | 1999-10-13 | 2000-10-13 | Short segments of dap-kinase |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1223970A4 (en) |
JP (1) | JP2003516122A (en) |
AU (1) | AU1082701A (en) |
CA (1) | CA2387541A1 (en) |
IL (1) | IL149093A0 (en) |
WO (1) | WO2001026678A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1566436A1 (en) * | 2002-11-21 | 2005-08-24 | Genomidea Inc | A method for isolating a nucleic acid having an intended functional property anda kit therefor |
EP1579011A2 (en) * | 2002-11-22 | 2005-09-28 | Isis Pharmaceuticals, Inc. | Modulation of death-associated protein kinase 1 expression |
US8961962B2 (en) | 2007-01-05 | 2015-02-24 | Mount Sinai School Of Medicine | Acid ceramidase and mammalian cell survival |
US9492514B2 (en) | 2012-06-01 | 2016-11-15 | Icahn School Of Medicine At Mount Sinai | Ceramide levels in the treatment and prevention of infections |
US9655953B2 (en) | 2004-07-01 | 2017-05-23 | Icahn School Of Medicine At Mount Sinai | Targeted protein replacement for the treatment of lysosomal storage disorders |
US9937246B2 (en) | 2013-03-14 | 2018-04-10 | Icahn School Of Medicine At Mount Sinai | Therapeutic acid ceramidase compositions and methods of making and using them |
US10350277B2 (en) | 2011-09-07 | 2019-07-16 | Icahn School Of Medicine At Mount Sinai | Ceramidase and cell differentiation |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005239695A (en) * | 2004-02-27 | 2005-09-08 | Mitsui Chemicals Inc | TGF-beta PRODUCTION-INHIBITING PEPTIDE |
US11141263B2 (en) | 2015-11-18 | 2021-10-12 | Shifamed Holdings, Llc | Multi-piece accommodating intraocular lens |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995010630A1 (en) * | 1993-10-12 | 1995-04-20 | Yeda Research And Development Co. Ltd. | Tumor suppressor genes, proteins encoded thereby and use of said genes and proteins |
-
2000
- 2000-10-13 IL IL14909300A patent/IL149093A0/en unknown
- 2000-10-13 JP JP2001529739A patent/JP2003516122A/en not_active Withdrawn
- 2000-10-13 CA CA002387541A patent/CA2387541A1/en not_active Abandoned
- 2000-10-13 EP EP00972123A patent/EP1223970A4/en not_active Withdrawn
- 2000-10-13 AU AU10827/01A patent/AU1082701A/en not_active Abandoned
- 2000-10-13 WO PCT/US2000/028312 patent/WO2001026678A1/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995010630A1 (en) * | 1993-10-12 | 1995-04-20 | Yeda Research And Development Co. Ltd. | Tumor suppressor genes, proteins encoded thereby and use of said genes and proteins |
Non-Patent Citations (10)
Title |
---|
COHEN ET AL.: "DAP-kinase is a Ca2+/calmodulin-dependent, cytoskeletal-associated protein kinase, with cell death-inducing functions that depend on its catalytic activity", EMBO JOURNAL, vol. 16, no. 5, 1997, pages 998 - 1008, XP002937776 * |
INBAL ET AL.: "DAP kinase links the control of apoptosis to matastasis", NATURE, vol. 390, 13 November 1997 (1997-11-13), pages 180 - 184, XP002937778 * |
KATZENELLENBOGEN ET AL.: "Hypermethylation of the DAP kinase CpG Island is a common alteration in B-cell malignancies", BLOOD, vol. 93, no. 12, June 1999 (1999-06-01), pages 4347 - 4353, XP002937779 * |
KAWAI ET AL.: "Death-associated protein kinase 2 is a new calcium/calmodulin-dependent protein kinase that signals apoptosis through its catalytic activity", ONCOGENE, vol. 18, no. 23, 15 June 1999 (1999-06-15), pages 3471 - 3480, XP002937781 * |
KAWAI ET AL.: "Duet is a novel serine/threonine kinase with Dbl-homology (DH) and pleckstrin-homology (PH) domains", GENE, vol. 227, no. 2, February 1999 (1999-02-01), pages 249 - 255, XP002937798 * |
KAWAI ET AL.: "ZIP kinase, a novel serine/threonine kinase which mediates apoptosis", MOLECULAR AND CELLULAR BIOLOGY, vol. 18, no. 3, March 1998 (1998-03-01), pages 1642 - 1651, XP002937780 * |
KIMCHI A.: "DAP kinase and DAP-3: Novel positive mediators of apoptosis", ANNALS OF THE RHEUMATIC DISEASES, vol. 58, no. SUPPLEMENT 1, November 1999 (1999-11-01), pages I14 - I19, XP002937782 * |
LIEPINSH ET AL.: "NMR structure of the death domain of the p75 neurotrophin receptor", EMBO JOURNAL, vol. 16, no. 16, 1997, pages 4999 - 5005, XP002937775 * |
SANJO ET AL.: "DRAKs, novel serine/threonine kinases related to death-associated protein kinase that trigger apoptosis", J. BIOL. CHEM., vol. 273, no. 44, 30 October 1998 (1998-10-30), pages 29066 - 29071, XP002937777 * |
See also references of EP1223970A4 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1566436A1 (en) * | 2002-11-21 | 2005-08-24 | Genomidea Inc | A method for isolating a nucleic acid having an intended functional property anda kit therefor |
EP1566436A4 (en) * | 2002-11-21 | 2006-04-19 | Genomidea Inc | A method for isolating a nucleic acid having an intended functional property anda kit therefor |
EP1579011A2 (en) * | 2002-11-22 | 2005-09-28 | Isis Pharmaceuticals, Inc. | Modulation of death-associated protein kinase 1 expression |
EP1579011A4 (en) * | 2002-11-22 | 2007-10-31 | Isis Pharmaceuticals Inc | Modulation of death-associated protein kinase 1 expression |
US9655953B2 (en) | 2004-07-01 | 2017-05-23 | Icahn School Of Medicine At Mount Sinai | Targeted protein replacement for the treatment of lysosomal storage disorders |
US8961962B2 (en) | 2007-01-05 | 2015-02-24 | Mount Sinai School Of Medicine | Acid ceramidase and mammalian cell survival |
US10350277B2 (en) | 2011-09-07 | 2019-07-16 | Icahn School Of Medicine At Mount Sinai | Ceramidase and cell differentiation |
US9492514B2 (en) | 2012-06-01 | 2016-11-15 | Icahn School Of Medicine At Mount Sinai | Ceramide levels in the treatment and prevention of infections |
US10159724B2 (en) | 2012-06-01 | 2018-12-25 | Icahn School Of Medicine At Mount Sinai | Ceramide levels in the treatment and prevention of infections |
US9937246B2 (en) | 2013-03-14 | 2018-04-10 | Icahn School Of Medicine At Mount Sinai | Therapeutic acid ceramidase compositions and methods of making and using them |
US10238721B2 (en) | 2013-03-14 | 2019-03-26 | Icahn School Of Medicine At Mount Sinai | Therapeutic acid ceramidase compositions and methods of making and using them |
US10918702B2 (en) | 2013-03-14 | 2021-02-16 | Icahn School Of Medicine At Mount Sinai | Therapeutic acid ceramidase compositions and methods of making and using them |
Also Published As
Publication number | Publication date |
---|---|
JP2003516122A (en) | 2003-05-13 |
WO2001026678A9 (en) | 2002-08-01 |
AU1082701A (en) | 2001-04-23 |
CA2387541A1 (en) | 2001-04-19 |
EP1223970A4 (en) | 2003-05-07 |
EP1223970A1 (en) | 2002-07-24 |
IL149093A0 (en) | 2002-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7141417B1 (en) | Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene | |
US20110288002A1 (en) | Novel bag proteins and nucleic acid molecules encoding them | |
KR20050090420A (en) | Metastin derivative and use thereof | |
EP1223970A1 (en) | Short segments of dap-kinase | |
AU760466B2 (en) | A novel inhibitor of programmed cell death | |
JPH10201492A (en) | Cdna clone he8cs41 coding new 7-transmembrane receptor | |
WO2000017345A1 (en) | Ly6h gene | |
JP4804714B2 (en) | Metastin derivatives and uses thereof | |
JP2003508011A (en) | Compositions, kits and methods relating to a novel tumor suppressor gene that is the human FEZ1 gene | |
US7160695B2 (en) | Molecules of the PYRIN/NBS/LRR protein family and uses thereof | |
US20210113685A1 (en) | Polypeptide drug against hepatitis b virus protein | |
JP2001509018A (en) | Human apoptosis-related protein encoded by DNA similar to P53-responsive mouse gene EI124 | |
AU774355B2 (en) | Novel bag proteins and nucleic acid molecules encoding them | |
US20110189711A1 (en) | Paad domain-containing polypeptides, encoding nucleic acids, and methods of use | |
US7119169B2 (en) | RelA-associated inhibitor, process for producing the same and utilization thereof | |
US7648963B2 (en) | Molecules of the PYRIN/NBS/LRR protein family and uses thereof | |
JP2003210183A (en) | HUMAN IkappaB-beta | |
JP2002503466A (en) | Retinoblastoma protein complex and retinoblastoma interacting protein | |
US20030224438A1 (en) | Novel molecules of the PYRIN/NBS/LRR protein family and uses thereof | |
CA2227508A1 (en) | Paip, a novel human protein which bridges the 3' and 5' end of mrna, and use thereof as a target for translational modulation to treat human disease | |
EP1367064A1 (en) | Inhibitors of proteins from the Rho-GEF family | |
CA2340617A1 (en) | Genes associated with neurotransmitter processing | |
WO2001060855A1 (en) | A novel human cell cycle control-related protein and a sequence encoding the same | |
WO2002098918A2 (en) | Novel targets for a therapeutic intervention in ebv related diseases | |
JP2005287418A (en) | Peptide having both cell killing and apoptosis defense property |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 149093 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2387541 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 529739 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000972123 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000972123 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/9-9/9, DRAWINGS, REPLACED BY NEW PAGES 1/11-11/11; DUE TO LATE TRANSMITTAL BY THE RECEIVINGOFFICE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000972123 Country of ref document: EP |